Fisher & Paykel Healthcare Corporation Limited announced today that it has selected Charlotte Walshe to participate in the Future Directors programme, with effect from 1 January 2024.
Ms Walshe has more than 20 years of experience across a range of sectors. This includes regulated global markets (healthcare, finance), high-tech manufacturing, export, technology and research institutes. Ms Walshe has also held chief executive roles with Jade Software Corporation and medical device manufacturer and health informatics provider Dynamic Controls, and she has been a director and trustee of a number of government organisations, private companies and research institutions.
She received a master of science in physics from the University of Canterbury, a bachelor of science (BSc) majoring in physics and mathematics, also from the University of Canterbury, and an Entrepreneurship Development Programme certificate from the Massachusetts Institute of Technology.
Future Directors is an initiative of the Institute of Directors aimed at giving talented executives exposure to a company board to gain governance skills and experience for a 12-to-18-month period. Future Directors attend board meetings to observe and participate in discussions, but they do not have voting rights.
"Charlotte’s experience and dynamism will be valuable assets," said Scott St John, Board Chair. "She has demonstrated leadership and expertise in both public and private sectors in R&D and highly regulated environments. I'm pleased to have the opportunity to work with her."
Ms Walshe said, “Fisher & Paykel Healthcare is an inspiring high-tech medical device company with global presence and recognition. I’m excited to learn from the Board, grow my governance skills and share my own insights.”
Fisher & Paykel Healthcare’s current Future Director, Tracey Barron, is completing her term with the company on 1 December 2023.
"We want to thank Ms Barron for her contribution to the Board, and we wish her all the best for the future,” said Mr St John.
Mr St John commended the Future Directors programme as a mutually beneficial initiative. "It allows the Board to benefit from new perspectives while giving the emerging directors an opportunity to develop their governance competencies. We are delighted to keep supporting it."
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in more than 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.
Media & Investor Contacts:
Head of Capital Markets & Investor Relations
+64 (0) 27 807 8073
GM Corporate Communications
+64 (0) 21 713 911
Authorised by Fisher & Paykel Healthcare Corporation Limited’s Board Chair.
Fisher & Paykel Healthcare Announces New Future Director Appointment
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
Providing Optimal Humidity for intubated patients
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Noninvasive respiratory support that provides a continuous distending pressure
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment